<?xml version='1.0' encoding='utf-8'?>
<document id="23293300"><sentence text="In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters."><entity charOffset="58-68" id="DDI-PubMed.23293300.s1.e0" text="boceprevir" /></sentence><sentence text="The inhibitory effect of boceprevir (BOC), an inhibitor of hepatitis C virus nonstructural protein 3 protease was evaluated in vitro against a panel of drug-metabolizing enzymes and transporters"><entity charOffset="25-35" id="DDI-PubMed.23293300.s2.e0" text="boceprevir" /><entity charOffset="37-40" id="DDI-PubMed.23293300.s2.e1" text="BOC" /><pair ddi="false" e1="DDI-PubMed.23293300.s2.e0" e2="DDI-PubMed.23293300.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23293300.s2.e0" e2="DDI-PubMed.23293300.s2.e1" /></sentence><sentence text=" BOC, a known substrate for cytochrome P450 (P450) CYP3A and aldo-ketoreductases, was a reversible time-dependent inhibitor (k(inact) = 0"><entity charOffset="1-3" id="DDI-PubMed.23293300.s3.e0" text="BOC" /></sentence><sentence text="12 minute(-1), K(I) = 6" /><sentence text="1 µM) of CYP3A4/5 but not an inhibitor of other major P450s, nor of UDP-glucuronosyltransferases 1A1 and 2B7" /><sentence text=" BOC showed weak to no inhibition of breast cancer resistance protein (BCRP), P-glycoprotein (Pgp), or multidrug resistance protein 2"><entity charOffset="1-3" id="DDI-PubMed.23293300.s6.e0" text="BOC" /></sentence><sentence text=" It was a moderate inhibitor of organic anion transporting polypeptide (OATP) 1B1 and 1B3, with an IC(50) of 18 and 4" /><sentence text="9 µM, respectively" /><sentence text=" In human hepatocytes, BOC inhibited CYP3A-mediated metabolism of midazolam, OATP1B-mediated hepatic uptake of pitavastatin, and both the uptake and metabolism of atorvastatin"><entity charOffset="66-75" id="DDI-PubMed.23293300.s9.e0" text="midazolam" /><entity charOffset="111-123" id="DDI-PubMed.23293300.s9.e1" text="pitavastatin" /><entity charOffset="163-175" id="DDI-PubMed.23293300.s9.e2" text="atorvastatin" /><entity charOffset="23-34" id="DDI-PubMed.23293300.s9.e3" text="BOC" /><pair ddi="false" e1="DDI-PubMed.23293300.s9.e3" e2="DDI-PubMed.23293300.s9.e3" /><pair ddi="false" e1="DDI-PubMed.23293300.s9.e3" e2="DDI-PubMed.23293300.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23293300.s9.e3" e2="DDI-PubMed.23293300.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23293300.s9.e3" e2="DDI-PubMed.23293300.s9.e2" /><pair ddi="false" e1="DDI-PubMed.23293300.s9.e0" e2="DDI-PubMed.23293300.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23293300.s9.e0" e2="DDI-PubMed.23293300.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23293300.s9.e0" e2="DDI-PubMed.23293300.s9.e2" /><pair ddi="false" e1="DDI-PubMed.23293300.s9.e1" e2="DDI-PubMed.23293300.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23293300.s9.e1" e2="DDI-PubMed.23293300.s9.e2" /></sentence><sentence text=" The inhibitory potency of BOC was lower than known inhibitors of CYP3A (ketoconazole), OATP1B (rifampin), or both (telaprevir)"><entity charOffset="27-30" id="DDI-PubMed.23293300.s10.e0" text="BOC" /><entity charOffset="66-71" id="DDI-PubMed.23293300.s10.e1" text="CYP3A" /><entity charOffset="73-85" id="DDI-PubMed.23293300.s10.e2" text="ketoconazole" /><entity charOffset="88-94" id="DDI-PubMed.23293300.s10.e3" text="OATP1B" /><entity charOffset="96-104" id="DDI-PubMed.23293300.s10.e4" text="rifampin" /><entity charOffset="116-126" id="DDI-PubMed.23293300.s10.e5" text="telaprevir" /><pair ddi="false" e1="DDI-PubMed.23293300.s10.e0" e2="DDI-PubMed.23293300.s10.e0" /><pair ddi="false" e1="DDI-PubMed.23293300.s10.e0" e2="DDI-PubMed.23293300.s10.e1" /><pair ddi="false" e1="DDI-PubMed.23293300.s10.e0" e2="DDI-PubMed.23293300.s10.e2" /><pair ddi="false" e1="DDI-PubMed.23293300.s10.e0" e2="DDI-PubMed.23293300.s10.e3" /><pair ddi="false" e1="DDI-PubMed.23293300.s10.e0" e2="DDI-PubMed.23293300.s10.e4" /><pair ddi="false" e1="DDI-PubMed.23293300.s10.e0" e2="DDI-PubMed.23293300.s10.e5" /><pair ddi="false" e1="DDI-PubMed.23293300.s10.e1" e2="DDI-PubMed.23293300.s10.e1" /><pair ddi="false" e1="DDI-PubMed.23293300.s10.e1" e2="DDI-PubMed.23293300.s10.e2" /><pair ddi="false" e1="DDI-PubMed.23293300.s10.e1" e2="DDI-PubMed.23293300.s10.e3" /><pair ddi="false" e1="DDI-PubMed.23293300.s10.e1" e2="DDI-PubMed.23293300.s10.e4" /><pair ddi="false" e1="DDI-PubMed.23293300.s10.e1" e2="DDI-PubMed.23293300.s10.e5" /><pair ddi="false" e1="DDI-PubMed.23293300.s10.e2" e2="DDI-PubMed.23293300.s10.e2" /><pair ddi="false" e1="DDI-PubMed.23293300.s10.e2" e2="DDI-PubMed.23293300.s10.e3" /><pair ddi="false" e1="DDI-PubMed.23293300.s10.e2" e2="DDI-PubMed.23293300.s10.e4" /><pair ddi="false" e1="DDI-PubMed.23293300.s10.e2" e2="DDI-PubMed.23293300.s10.e5" /><pair ddi="false" e1="DDI-PubMed.23293300.s10.e3" e2="DDI-PubMed.23293300.s10.e3" /><pair ddi="false" e1="DDI-PubMed.23293300.s10.e3" e2="DDI-PubMed.23293300.s10.e4" /><pair ddi="false" e1="DDI-PubMed.23293300.s10.e3" e2="DDI-PubMed.23293300.s10.e5" /><pair ddi="false" e1="DDI-PubMed.23293300.s10.e4" e2="DDI-PubMed.23293300.s10.e4" /><pair ddi="false" e1="DDI-PubMed.23293300.s10.e4" e2="DDI-PubMed.23293300.s10.e5" /></sentence><sentence text=" BOC was a substrate for Pgp and BCRP but not for OATP1B1, OATP1B3, OATP2B1, organic cation transporter, or sodium/taurocholate cotransporting peptide"><entity charOffset="108-114" id="DDI-PubMed.23293300.s11.e0" text="sodium" /><entity charOffset="115-127" id="DDI-PubMed.23293300.s11.e1" text="taurocholate" /><entity charOffset="1-12" id="DDI-PubMed.23293300.s11.e2" text="BOC" /><pair ddi="false" e1="DDI-PubMed.23293300.s11.e2" e2="DDI-PubMed.23293300.s11.e2" /><pair ddi="false" e1="DDI-PubMed.23293300.s11.e2" e2="DDI-PubMed.23293300.s11.e0" /><pair ddi="false" e1="DDI-PubMed.23293300.s11.e2" e2="DDI-PubMed.23293300.s11.e1" /><pair ddi="false" e1="DDI-PubMed.23293300.s11.e0" e2="DDI-PubMed.23293300.s11.e0" /><pair ddi="false" e1="DDI-PubMed.23293300.s11.e0" e2="DDI-PubMed.23293300.s11.e1" /></sentence><sentence text=" Overall, our data suggest that BOC has the potential to cause pharmacokinetic interactions via inhibition of CYP3A and CYP3A/OATP1B interplay, with the interaction magnitude lower than those observed with known potent inhibitors"><entity charOffset="32-34" id="DDI-PubMed.23293300.s12.e0" text="BOC" /><entity charOffset="110-112" id="DDI-PubMed.23293300.s12.e1" text="CYP3A" /><entity charOffset="120-122" id="DDI-PubMed.23293300.s12.e2" text="CYP3A" /><pair ddi="false" e1="DDI-PubMed.23293300.s12.e0" e2="DDI-PubMed.23293300.s12.e0" /><pair ddi="false" e1="DDI-PubMed.23293300.s12.e0" e2="DDI-PubMed.23293300.s12.e1" /><pair ddi="false" e1="DDI-PubMed.23293300.s12.e0" e2="DDI-PubMed.23293300.s12.e2" /><pair ddi="false" e1="DDI-PubMed.23293300.s12.e1" e2="DDI-PubMed.23293300.s12.e1" /><pair ddi="false" e1="DDI-PubMed.23293300.s12.e1" e2="DDI-PubMed.23293300.s12.e2" /></sentence><sentence text=" Conversely, pharmacokinetic interactions of BOC, either as a perpetrator or victim, via other major P450s and transporters tested are less likely to be of clinical significance"><entity charOffset="45-49" id="DDI-PubMed.23293300.s13.e0" text="BOC" /></sentence><sentence text=" The results from clinical drug-drug interaction studies conducted thus far are generally supportive of these conclusions" /><sentence text="" /></document>